KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Rigel Pharmaceuticals (RIGL) Receivables - Net (2016 - 2025)

Rigel Pharmaceuticals has reported Receivables - Net over the past 12 years, most recently at $51.8 million for Q4 2025.

  • Quarterly results put Receivables - Net at $51.8 million for Q4 2025, up 24.39% from a year ago — trailing twelve months through Dec 2025 was $51.8 million (up 24.39% YoY), and the annual figure for FY2025 was $51.8 million, up 24.39%.
  • Receivables - Net for Q4 2025 was $51.8 million at Rigel Pharmaceuticals, up from $45.9 million in the prior quarter.
  • Over the last five years, Receivables - Net for RIGL hit a ceiling of $142.2 million in Q1 2021 and a floor of $3.0 million in Q1 2025.
  • Median Receivables - Net over the past 5 years was $25.5 million (2023), compared with a mean of $31.6 million.
  • Biggest five-year swings in Receivables - Net: skyrocketed 1372.0% in 2021 and later plummeted 89.28% in 2022.
  • Rigel Pharmaceuticals' Receivables - Net stood at $15.5 million in 2021, then grew by 29.27% to $20.0 million in 2022, then surged by 52.75% to $30.6 million in 2023, then skyrocketed by 36.22% to $41.6 million in 2024, then increased by 24.39% to $51.8 million in 2025.
  • The last three reported values for Receivables - Net were $51.8 million (Q4 2025), $45.9 million (Q3 2025), and $39.9 million (Q2 2025) per Business Quant data.